



**PRIVATE FUNDING OPPORTUNITIES: APR 28, 2017**

---

Please contact Corporate & Foundation Relations in the Office of Development at [devcfr@mgh.harvard.edu](mailto:devcfr@mgh.harvard.edu) if you wish to submit a proposal in response to any of these opportunities. Note that proposals are still routed through the standard InfoEd/Research Management process.

Please be aware that any grant that brings in less than **15% in indirect costs (IDC)** will need to be supplemented up to the 15% equivalent by existing investigator or departmental sundry funds. Resolution of this issue must occur prior to submission of the award. Training fellowships from foundations, public charity, and non-profit organizations are excluded from this minimum IDC requirement.

**1. Familial RUNX1 Grant Program: Familial RUNX1 Patient Samples Grant, Alex's Lemonade Stand Foundation for Childhood Cancer (ALSF)**

ALSF is committed to creating opportunities for new and innovative research into treatments and cures for childhood cancers. The Babich Family Foundation is dedicated to advancing areas of research of particular importance to families affected by familial platelet disorder leading to acute myeloid leukemia (FPD/AML) due to monoallelic germline RUNX1 mutations (OMIM:601399), with the ultimate goal of developing effective therapies to prevent the onset of AML. ALSF and The Babich Family Foundation have partnered to raise awareness and accelerate research around FPD/AML.

The purpose of the grant is to fund research in strategies leading to the development of therapies to prevent the transition from pre-leukemia to leukemia for patients with FPD/AML. Projects should focus on leukemia caused by familial RUNX1 mutations rather than sporadic AML with somatic RUNX1 mutations.

Research Directions of Interest:

- Studies that develop our understanding of the biological basis for disease progression in FPD/AML associated with RUNX1 mutations.
- Studies to develop potential therapies to limit disease progression in individuals with FPD/AML.
- Development of in vitro and in vivo model systems (including but not limited to human cell, mouse or zebrafish) that increase the understanding of disease pathogenesis, test mechanistic hypotheses, or that provide a suitable evaluation platform for the discovery of potential therapies.



Do you want to learn more about identifying external funding opportunities? See [ECOR's website](#) for information on the funding opps database, **COS Pivot** or contact Amy Robb <[arobb@mgh.harvard.edu](mailto:arobb@mgh.harvard.edu)> to schedule an individual consultation or group training session.

Award Amount: \$250,000-\$500,000 paid over 2 years  
Indirect Costs: None  
LOI Deadline: Jul 1, 2017  
Website: <http://www.alexlemonade.org/grants/runx1>

## **2. Damon Runyon-Rachleff Innovation Award (Innovation Award), Damon Runyon Cancer Research Foundation**

The Damon Runyon-Rachleff Innovation Award is designed to provide support for the next generation of exceptionally creative thinkers with "high-risk/high-reward" ideas that have the potential to significantly impact our understanding of and/or approaches to the prevention, diagnosis or treatment of cancer.

The Innovation Award is specifically designed to provide funding to extraordinary early career researchers who have an innovative new idea but lack sufficient preliminary data to obtain traditional funding. It is not designed to fund incremental advances. The research supported by the award must be novel, exceptionally creative and, if successful, have the strong potential for high impact in the cancer field.

Awards are made to institutions for support of the Damon Runyon-Rachleff Innovation Investigators. All awards are approved by the Board of Directors of the Damon Runyon Cancer Research Foundation acting upon the recommendation of the Innovation Award Committee.

Applications will be evaluated based on the following:

- The applicant's capacity to conduct bold, exceptionally creative research.
- The novelty and creativity of the proposed research. Incremental research will not be funded.
- The potential of the proposed research to lead to advances that will significantly impact the prevention, diagnosis, treatment or basic understanding of cancer.
- The applicant's lack of resources to pursue the proposed research.

Basic and translational/clinical projects will be considered. Applications will be accepted from all scientific disciplines provided that the proposed research meets the selection criteria.

Award Amount: \$300,000 paid over 2 years  
Indirect Costs: None  
Application Deadline: Jul 6, 2017  
Website: <https://www.damonrunyon.org/for-scientists/application-guidelines/innovation>

### **3. EH Direct Grant Program, Enduring Hearts (EH)** New

Enduring Hearts funds the most promising research being conducted to increase the longevity of transplanted human organs and related tissue transplants. Their grant awards specifically target research benefiting pediatric heart transplant recipients.

As a nonprofit organization, Enduring Hearts works with their scientific advisory board to identify and award operating grants for research projects in organ transplantation to established members of academic staff at universities, transplant centers and research institutes.

Enduring Hearts gives priority to clinical research projects and new emerging technologies focused on understanding the cause, development and prevention of human transplantation diseases, including organ injury and rejection, viral infection and late graft deterioration.

Award Amount: \$200,000

Indirect Costs: 15%

Application Deadline: Jun 10, 2017

Website: <https://www.enduringhearts.org/grant-deadlines/>

### **4. Health Services Research Pipeline Grant, Foundation for Physical Therapy (FPT)** New

This grant is to be awarded to support research that examines mechanisms by which patients obtain physical therapy-related health care, how much such care costs, and what outcomes are observed in these patients.

Research efforts should focus on the identification of the most effective ways to organize, manage, finance, and deliver high quality physical therapy-related care while potentially reducing medical errors and improving safety for patients.

Award Amount: \$50,000 for 1 year

Indirect Costs: None

Application Deadline: Aug 3, 2017

Website: <http://www.foundation4pt.org/apply-for-funding/research-grants/>

### **5. Magistro Family Foundation Research Grant (MFFRG), Foundation for Physical Therapy (FPT)**

The Foundation, like the physical therapy profession, is dedicated to the goal of improving the quality and delivery of patient care. The Foundation accomplishes this goal by providing support to emerging investigators to promote scientifically based and clinically relevant research related to the effectiveness of physical therapist practice.

Studies should seek to do one or more of the following:

- Evaluate the clinical effectiveness of therapeutic interventions

- Assess the interaction between patient characteristics and therapeutic methods
- Explore the scientific basis for interventions used in physical therapy
- Address an item identified in the APTA Research.

In addition, priority will be given to studies which:

- Have direct application to the practice of physical therapy
- Address the need for measurable outcomes
- Ask a new question important to intervention or its validation
- Address a previously asked question with a new methodology, different sampling strategy or a different form of analysis.

FPT would prefer that proposed studies:

- Have obtained matching funds or in-kind services
- Provide the basis for larger-scale submissions for funding to external agencies (e.g., NIH).
- Preferred consideration will be given to studies that examine not only the therapeutic effectiveness of interventions, but also their cost effectiveness.

Award Amount: \$100,000 paid over 1-2 years

Indirect Costs: None

LOI Deadline: Jun 1, 2017

Website: <http://www.foundation4pt.org/apply-for-funding/research-grants/>

## **6. U.S. Corporate Grants, Gilead Sciences, Inc./Gilead Sciences Pty Ltd**

Gilead is inspired by the work that its grantees do to improve access and eliminate barriers to healthcare, advance education among patients and healthcare professionals, and help build strong local communities. Gilead welcomes funding requests for innovative, high-impact projects that relate to at least one of five core therapeutic areas: HIV/AIDS, liver diseases, hematology and oncology, inflammatory and respiratory diseases, and cardiovascular conditions. Gilead considers a number of factors when reviewing grants, but it is most important for applications to demonstrate a strong commitment to - and capacity for - delivering the specific services their funded grant would support.

- Patient Community Support
- Medical and Scientific Support
- Charitable Donations

Award Amount: Unspecified

Indirect Costs: None

Application Deadline: Continuous

Website: <http://www.gilead.com/responsibility/corporate-contributions/north-america>

**7. Gilead Sciences Research Scholars Program in Cardiovascular Disease, Gilead Sciences, Inc./Gilead Sciences Pty Ltd**

The Program is designed to support basic and clinical research in the field of cardiovascular disease.

Award Amount: \$130,000 paid over 2 years

Indirect Costs: 10%

Application Deadline: Jul 7, 2017

Website: <http://researchscholarscvd.gilead.com>

**8. Promising Innovations Grant, Kendal Charitable Funds**

Kendal Charitable Funds, via the Lloyd Lewis Fund for Promising Innovations, is seeking ideas that can enhance the lives of an aging population through services and research. The organization is interested in developing new understandings and awareness of issues and opportunities in support of this initiative. It will give priority to projects that have significant potential for change and replication.

The proposed project must focus on the following topic:

With 90 percent of individuals over age 65 saying they want to live at home, successful and replicable aging in place models continue to challenge aging services. At the heart of this challenge is the risk of social isolation many older adults may face. Kendal Charitable Funds seeks proposals that support aging in place and combat isolation of older adults through engagement in purposeful and meaningful ways within the greater community, designed to affirm their value and connectedness. It hopes to identify factors that lead to isolation and to address them before and/or after they occur, especially utilizing new, replicable models.

Award Amount: \$50,000 paid over 2 years

Indirect Costs: Unpublished

LOI Deadline: May 19, 2017

Website: <http://www.kendalcharitablefunds.org/2017-grant-opp/>

**9. Independent Grants for Learning & Change (IGLC): Track 2 - Call for Grant Applications (CGA) - Advances in the Treatment of Renal Cell Carcinoma, Pfizer, Inc.**

The mission of Pfizer Independent Grants for Learning & Change (IGL&C) is to partner with the global healthcare community to improve patient outcomes in areas of mutual interest through support of measurable learning and change strategies. "Independent" means that the projects funded by Pfizer are the full responsibility of the recipient organization. Pfizer has no influence over any aspect of the projects and only asks for reports about the results and the impact of the projects in order to share them publicly.

Through this CGA Pfizer encourages organizations to submit grant requests that, if funded, will support education in a specific disease state, therapeutic area, or broader area of educational need. Educational activities should not be focused on products specific to Pfizer.

Geographic Scope:

- North America
- Europe

Clinical Area: Renal Cell Carcinoma (RCC)

Specific Area of Interest for this CGA:

It is Pfizer's intent to support continuing professional development programs (CME/CE) for medical oncologists, urologists, nurses, nurse practitioners, physician assistants and other healthcare professionals involved in the care and treatment of patients with RCC. Proposed programs should focus on understanding adjuvant therapy in oncology. Other topics of interest are current and future treatment sequencing with tyrosine-kinase inhibitors (TKIs) and adverse event management for patients with RCC.

All activity types will be considered through this CGA including single or multiple live events, satellite symposia, workshops, online courses, print materials and other enduring materials. An activity taking place alongside the 18th Annual Meeting of the Society of Urologic Oncology in November 2017 is of particular interest. Multi-faceted proposals can include activities taking place through December 2018. Efforts should be made to encourage interaction, incorporate patient case discussions, and provide opportunities to extend and reinforce learning beyond the live setting (e.g. practice tools, algorithms, reference guides).

Award Amount: \$750,000 paid over 2 years

Indirect Costs: 28%

Application Deadline: May 31, 2017

Website: [http://www.pfizer.com/responsibility/grants\\_contributions/grants\\_process](http://www.pfizer.com/responsibility/grants_contributions/grants_process)

## 10. Health Data for Action, Robert Wood Johnson Foundation (RWJF)

The HD4A program will fund innovative research that uses the available data to answer important research questions. Applicants under this Call for Proposals (CFP) will write a proposal for a research study using data from either the Health Care Cost Institute (HCCI) or athenahealth. Successful applicants will be provided with access to these data, which are described in greater detail below. The HCCI and athenahealth data provide a wealth of private claims data and rich detail on care delivery and patient obesity-related measures, respectively. The proposed studies should enable relevant, innovative, and actionable research that uses the available data to answer important, policy-relevant questions. Projects may be generated from disciplines including health services research; economics; sociology; program evaluation; political science; public policy; public health; public administration; law; business

administration; or other related fields. Use of the data under this CFP is restricted to noncommercial use.

Award Amount: \$150,000 for 1 year

Indirect Costs: 12%

Application Deadline: May 24, 2017

Website: <http://www.rwjf.org/en/library/funding-opportunities/2017/health-data-for-action.html>